Intranasal OXT

Phase 2Small molecule

UUniversity Hospital, Basel, Switzerland

Intranasal OXT is one of 4 small molecule programs targeting Central diabetes insipidus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Central Diabetes InsipidusActive, not recruiting

Central Diabetes InsipidusPhase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Central Diabetes Insipidus

#DrugCompanyPhaseTrials

Pitocin

RRetrophin

Phase 2

1 2

Desmopressin Melt

Ferring

Phase 3

1 3

Intranasal OXT

UUniversity Hospital, Basel, Switzerland

Phase 2

1 4

Midomafetamine

LLykos Therapeutics

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Central Diabetes Insipidus

NCT06036004

Clinical

Trials by Indication[1]

Central diabetes insipidus1 trial

Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus

Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 2·NCT06036004·112 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intranasal OXT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intranasal OXT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intranasal OXT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Basel, Switzerland company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity Hospital, Basel, Switzerland

Intranasal OXT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Central diabetes insipidus1 trial

References

Drug Info

Quick Facts

Related News